These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29454033)

  • 21. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use.
    Senthong AJ; Taneepanichskul S
    J Med Assoc Thai; 2009 Apr; 92(4):461-5. PubMed ID: 19374294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between progesterone receptor level in endometrium and bleeding pattern in depot medroxyprogesterone acetate users.
    Chotnopparatpattara P; Taneepanichskul S; Treratanachat S; Charuruks N
    J Med Assoc Thai; 2003 Feb; 86(2):172-7. PubMed ID: 12678156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK.
    Kyvernitakis I; Kostev K; Nassour T; Thomasius F; Hadji P
    Osteoporos Int; 2017 Jan; 28(1):291-297. PubMed ID: 27461017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medroxyprogesterone acetate as a contraceptive for female drug addicts.
    Mark I
    Scand J Soc Med; 1983; 11(3):75-80. PubMed ID: 6230717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A postconization hematometra revealed a rare case of endocervical bone metaplasia.
    Giannella L; Gelli MC; Mfuta K; Prandi S
    J Low Genit Tract Dis; 2014 Jan; 18(1):E19-22. PubMed ID: 23959299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematometra in postmenarchal adolescent girls: a report of two cases.
    Dadhwal V; Mittal S; Kumar S; Barua A
    Gynecol Obstet Invest; 2000; 50(1):67-9. PubMed ID: 10895033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
    Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
    Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate.
    Dilshad H; Yousuf RI; Shoaib MH; Jamil S; Khatoon H
    Am J Med Sci; 2016 Nov; 352(5):487-492. PubMed ID: 27865296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous uterine rupture in a nulligravida female presenting with unexplained recurrent hematometra.
    Gowda M; Garcia L; Maxwell E; Malik R; Gulyaeva L; Tsai MC
    Clin Exp Obstet Gynecol; 2010; 37(1):60-2. PubMed ID: 20420285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.
    Segall-Gutierrez P; Xiang AH; Watanabe RM; Trigo E; Stanczyk FZ; Liu X; Jurow R; Buchanan TA
    Contraception; 2012 Jan; 85(1):36-41. PubMed ID: 22067800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
    Langer RD; Landgren BM; Rymer J; Helmond FA;
    Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
    Sonalkar S; McClusky J; Hou MY; Borgatta L
    Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users.
    Tantiwattanakul P; Taneepanichskul S
    Contraception; 2004 Oct; 70(4):277-9. PubMed ID: 15451330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women.
    Connor PD; Tavernier LA; Thomas SM; Gates D; Lytton SM
    J Am Board Fam Pract; 2002; 15(1):7-10. PubMed ID: 11841143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.